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Abstract
Background:
Alcoholic hepatitis is a chronic, inflammatory liver disease that is on the rise in the United States.
Traditionally, the progression of severe alcoholic hepatitis has been slowed with a 28-day course of
prednisolone. However, since corticosteroids such as prednisolone have been associated with increased risk of
infection and multiple unpleasant side effects, newer research is aimed at using pentoxifylline (PTX) as an
alternative treatment. PTX has been shown to have a better safety profile than prednisolone, but its
effectiveness in the treatment of severe alcoholic hepatitis is in question. Therefore, the aim of this systematic
review is to further evaluate the efficacy of PTX as compared to prednisolone in the treatment of severe
alcoholic hepatitis in adult patients.
Methods:
An exhaustive search using MEDLINE-Ovid, MEDLINE-Pub-Med, Web of Science, and Up-To-Date was
performed using the terms: pentoxifylline, corticosteroids, and alcoholic hepatitis. Animal studies, articles
published over ten years ago, and articles written in non-English languages were excluded from the search.
Only randomized-controlled trials were considered for review. All articles were assessed for quality using the
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) criteria.
Results:
Three studies met criteria and were used in this systematic review. The STOPAH trial, an RCT by Thursz et al
found that PTX is less effective than Prednisolone at treating severe alcoholic hepatitis in adults in the
prevention of mortality at 28 days (P < 0.06). In a small, RCT by Park et al, it was found that PTX is not
inferior nor superior to prednisolone in the treatment of severe alcoholic hepatitis. A third RCT by De et al
indicated that PTX was superior to prednisolone in the regards to survival at 3 months (P<0.05).
Conclusion:
The overall quality of evidence supporting the use of PTX rather than prednisolone in the treatment of severe
alcoholic hepatitis in adult patients is low. Although there is indication that PTX may be a safer alternative or
perhaps equivalent to prednisolone in select patients, there is a lack of evidence from good RCTs to support
this theory. Based on the results discussed in this systematic review, further investigation with larger, longer
RCTs is warranted.
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Abstract   
 
Background:  
 
Alcoholic hepatitis is a chronic, inflammatory liver disease that is on the rise in the United 
States. Traditionally, the progression of severe alcoholic hepatitis has been slowed with a 28-day 
course of prednisolone. However, since corticosteroids such as prednisolone have been 
associated with increased risk of infection and multiple unpleasant side effects, newer research is 
aimed at using pentoxifylline (PTX) as an alternative treatment. PTX has been shown to have a 
better safety profile than prednisolone, but its effectiveness in the treatment of severe alcoholic 
hepatitis is in question. Therefore, the aim of this systematic review is to further evaluate the 
efficacy of PTX as compared to prednisolone in the treatment of severe alcoholic hepatitis in 
adult patients.  
 
Methods:   
 
An exhaustive search using MEDLINE-Ovid, MEDLINE-Pub-Med, Web of Science, and Up-
To-Date was performed using the terms: pentoxifylline, corticosteroids, and alcoholic hepatitis. 
Animal studies, articles published over ten years ago, and articles written in non-English 
languages were excluded from the search. Only randomized-controlled trials were considered for 
review. All articles were assessed for quality using the Grading of Recommendations, 
Assessment, Development, and Evaluation (GRADE) criteria. 
 
Results:   
 
Three studies met criteria and were used in this systematic review. The STOPAH trial, an RCT 
by Thursz et al found that PTX is less effective than Prednisolone at treating severe alcoholic 
hepatitis in adults in the prevention of mortality at 28 days (P < 0.06). In a small, RCT by Park et 
al, it was found that PTX is not inferior nor superior to prednisolone in the treatment of severe 
alcoholic hepatitis. A third RCT by De et al indicated that PTX was superior to prednisolone in 
the regards to survival at 3 months (P<0.05).  
 
Conclusion:  
 
The overall quality of evidence supporting the use of PTX rather than prednisolone in the 
treatment of severe alcoholic hepatitis in adult patients is low. Although there is indication that 
PTX may be a safer alternative or perhaps equivalent to prednisolone in select patients, there is a 
lack of evidence from good RCTs to support this theory. Based on the results discussed in this 
systematic review, further investigation with larger, longer RCTs is warranted.  
 
Keywords:  Pentoxifylline, corticosteroids, treatment, alcoholic hepatitis 
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Pentoxifylline vs. Prednisolone: A Comparison of Efficacy in the 
Treatment of Severe Alcoholic Hepatitis in Adult Patients 
BACKGROUND 
 Alcoholic hepatitis is a chronic, inflammatory liver disease that is on the rise in the 
United States.1 Associated with the toxic effects of excessive alcohol consumption, alcoholic 
hepatitis leads to irreversible liver pathologies including fatty liver disease, cirrhosis, and 
eventually hepatocellular necrosis. Traditionally, the progression of severe alcoholic hepatitis has 
been slowed with a 28-day course of prednisolone. However, since corticosteroids such as 
prednisolone have been associated with increased risk of infection, newer research is aimed at 
using pentoxifylline (PTX) as an alternative treatment.2 PTX works to improve erythrocyte 
flexibility by lowering blood viscosity, achieving healthier blood flow.3 PTX is also an inhibitor 
of tissue necrosis factor (TNF) synthesis and since TNF is increased in patients with alcoholic 
hepatitis,4 the drug is being considered as an off-label treatment for this disease.  
 While PTX has been associated with arrhythmias, dyspepsia, and  nausea, prolonged 
treatment with prednisolone has been shown to cause several serious adverse drug reactions 
including, but not limited to adrenal insufficiency, diabetes mellitus, hypertension, congestive 
heart failure, pancreatitis, and growth suppression.3,5 Although PTX has a better safety profile 
than prednisolone, there are arguments that it may not be as effective in the treatment of severe 
alcoholic hepatitis. However, with comparable costs3,6 and fewer side effects, it is an alternative 
treatment worth consideration. Therefore, the aim of this systematic review is to further evaluate 
the efficacy of PTX as compared to prednisolone in the treatment of severe alcoholic hepatitis in 
adult patients.  
METHODS 
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An exhaustive literature search using MEDLINE-Ovid, MEDLINE-Pub-Med, Web of 
Science, and Up-To-Date was performed using the terms: pentoxifylline, corticosteroids, and 
alcoholic hepatitis. Exclusion criteria included animal studies and non-English articles. All 
studies considered for this review were randomized controlled trials published within the past 10 
years. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) 
criteria was used to assess all articles considered for the review.7 
RESULTS 
The above search resulted in 38 total articles, which were then screened for relevance. Of 
the 38 articles, three met the inclusion criteria and were used for this systematic review.4,8,9 As 
previously stated, all articles included in this review are RCTs and were evaluated using the 
GRADE criteria (see Table I). 
Thursz et al 
This double-blind, randomized control trial8 known as the STOPAH trial, was constructed 
to evaluate the effects of PTX in comparison to prednisolone in the treatment of severe alcoholic 
hepatitis in adult patients. Its primary endpoint was mortality at 28 days. Secondary endpoints 
included liver transplant or death at 90 days and 1 year. However, funding was limited for the 
trial and therefore, these secondary endpoints could not be evaluated for all enrolled patients. 
The STOPAH trial consisted of 1103 patients with clinical diagnoses of severe alcoholic 
hepatitis, randomly divided into one of four groups: 276 were selected for the placebo group, 277 
for the prednisolone group, 276 for the PTX group, and 274 for the prednisolone/PTX group. 
While those in the prednisolone group received 40mg of prednisolone and a PTX dose-
equivalent placebo per day, those in the PTX group received 400mg of PTX three times daily 
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(TID) with a prednisolone-dose equivalent placebo. Those in the prednisolone/PTX group 
received 40mg of prednisolone per day, as well as 400mg of PTX three times daily.8 
The STOPAH trial's exclusion criteria included patients with jaundice > 3 months, other 
potential  cause of the hepatitis, abstinence from alcohol for 2 months or longer prior to the trial, 
patients with aspartate transaminase (AST) > 500IU/L, patients with alanine transaminase (ALT) 
> 300IU/L, and anyone with prior entry into the study within the 6 months preceding 
randomization.8 
 A logistic regression analysis was used to compare the rates of mortality at 28 days 
between the treated and untreated groups of patients. In the placebo group, mortality at 28 days 
was 17%. Mortality at 28 days in the prednisolone group was 14% with an odds ratio of 0.72 
([95% CI] 0.52-1.01, P: 0.06). After adjustments were made for baseline categories (age, 
encephalopathy, WBC, PT, serum bilirubin, blood creatinine, and blood urea) and factorial 
design, this odds ratio improved to 0.61 ([95% CI] 0.41-0.91, P: 0.02).  In the PTX group, 
mortality at 28 days was 19% with an odds ratio of 1.07 ([95% CI] 0.77-1.49, P: 0.69). No 
adjustments were made for this group. The prednisolone/PTX group had 13% mortality at 28 
days. For the participants who were evaluated for secondary endpoints, the effects of 
prednisolone vs. PTX were nonsignificant.8  
Park et al 
In this randomized non-inferiority RCT,4 121 patients were divided into two treatment 
groups to evaluate the effectiveness of PTX as compared to prednisolone in the treatment of 
severe alcoholic hepatitis in adult patients. While 59 patients received 40mg of prednisolone 
daily, 62 received 400mg of PTX three times daily. Survival at 1 month of treatment was the 
primary outcome of this study.4 
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The criteria eligibility of this study was closely matched to that of prior studies. Inclusion 
criteria required the clinical diagnosis of severe alcoholic hepatitis, a minimum consumption of 
40mg of alcohol per day within the 3 months preceding the study, and adult patients aged 20-75 
years. Patients were not considered for this study if they had recent history of bacterial infection, 
pancreatitis, GI bleeding, renal impairment, or other causes of liver disease.4 
All quantitative variables were compared using the student t-test, whereas all qualitative  
variables were expressed in percentages based off of results from x2 or Fisher exact tests.  A pre-
defined inferiority margin was set at 15%. The difference in probability of survival between 
patients treated with prednisolone vs. PTX ([95% CI] 4.2%-28.7%, P: 0.08) exceeded that of the 
pre-defined inferiority margin, indicating that the difference in survival was not significant and 
inconclusive. Therefore, this evidence from this study cannot establish PTX as non-inferior to 
prednisolone.4 
De et al 
This randomized, double-blinded RCT9 consisted of  68 patients that were divided into 
two treatment groups: the prednisolone group and the PTX group. The primary purpose of this 
study was  to evaluate the effectiveness of PTX as compared to prednisolone in the treatment of 
severe alcoholic hepatitis in adult patients.  While 28 patients received 40mg of prednisolone 
daily, 34 received 400mg of PTX three times daily. Those taking prednisolone were given 
placebo tablets twice daily to maintain blinding. The primary outcome of this study was survival 
at 3 months.9 
Candidates were carefully selected to participate in this study using strict criteria 
eligibility. Patients considered for the study were required to have a history of chronic alcohol 
intake with a minimum consumption of 50g/day, AST:ALT > 2:1, or AST > 500IU/L and ALT > 
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200IU/L. Exclusion criteria included patients who were abstinent from alcohol anytime within 
the month preceding the study and patients with other causes of liver disease, HIV, peritonitis, 
GI bleeding, pancreatitis, hypertension, diabetes, heart failure, pulmonary disease, or 
malignancy.9  
Treatment with Prednisolone was discontinued prematurely in 13 patients and treatment 
with PTX was discontinued early in five patients due to life-threatening complications. All 
statistical data was analyzed using the student t-test, x2 test, or Fisher exact test.  At 3 months, 
35.29% of patients in the prednisolone group and 14.71% of patients in the PTX group had died 
(P < 0.05). 9 
DISCUSSION 
The three studies discussed in this review are inconsistent with their results. However, the 
De et al study9 followed patients for 90 days and was able to demonstrate a 42% reduction in 
mortality in patients taking PTX. Therefore, PTX still has potential as an alternative to 
prednisolone but more research is necessary. Other considerations in managing severe alcoholic 
hepatitis is the safety and cost of each medication. Comparisons of the cost and safety of 
prednisolone versus PTX indicate that PTX is a safer option. Whereas PTX has been associated 
with arrhythmias and GI upset,3 prednisolone has been linked to multiple serious side effects 
including adrenal insufficiency, diabetes mellitus, hypertension, congestive heart failure, 
pancreatitis, and growth suppression...etc.3,5 In addition to the common reactions of dyspepsia 
and nausea associated with PTX, prolonged treatment with prednisolone is likely to result in 
fluid retention, hypokalemia, hirsutism, skin changes, and depression. Furthermore, because of 
its many adverse drug reactions, prednisolone should not be used in patients with recent 
infection, hypertension, recent myocardial infarction, diabetes mellitus, seizure disorders, 
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irritable bowel disease, osteoporosis, thyroid disorders, or any other form of 
immunosuppression.5 Since adults with a history of chronic alcoholism and alcoholic hepatitis 
are likely to have one or more of these co-morbidities, an alternative treatment to prednisolone 
should be an important focus of future medical research.  
While prednisolone costs about fifty dollars per month, the average monthly cost of PTX 
is sixty-four dollars. If PTX proves to be effective in the treatment of severe alcoholic hepatitis 
in adult patients, then the additional fourteen-dollar cost per month greatly outweighs the health 
risks and subsequent additional medical costs associated with prednisolone. Therefore, additional 
research in this area of medicine is of great significance.  
Thursz et al 
Although the STOPAH trial8 is a strong RCT, it presents some weaknesses. The 
STOPAH trial is currently the largest RCT to evaluate and compare the effectiveness of 
prednisolone vs. PTX in the treatment of severe alcoholic hepatitis in adult patients. The blinding 
and randomization process utilized to conduct this trial allowed for a strong study with minimal 
concern for bias.  Inclusion criteria ensured that all patients had similar clinical diagnoses and 
prognoses without additional causes of liver disease, making skewed results related to other 
health problems unlikely.  
The STOPAH trial's biggest limitation was its lack of funding, which resulted in the 
inability to evaluate mortality after 28 days in all patients enrolled in the study.8 While baseline 
adjustments were made for the prednisolone group, there is no mention of baseline adjustments 
for the PTX group. However, despite these limitations, the results of the STOPAH trial in 
regards to mortality at 28 days remain significant.  
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The results of the STOPAH trial8 indicate decreased mortality in adult patients with 
severe alcoholic hepatitis taking prednisolone vs. those taking PTX at 28 days of treatment (P < 
0.02). However, since funding only allowed for 28 days of follow-up, mortality at later dates 
could not be effectively evaluated for either treatment group. Additionally, infection occurred in 
13% of patients receiving prednisolone as compared to 7% of patients who did not receive this 
drug, indicating that PTX may be a safer option8. There is a chance that with this trial's early 
termination, long-term benefits of PTX vs. prednisolone may have been missed. This may 
prompt further research to evaluate PTX as a safer alternative in the chronic treatment of adult 
patients with severe alcoholic hepatitis.    
Park et al 
Although this is an RCT, there are significant limitations that make its results 
questionable. This was an open-trial, indicating that there was no blinding amongst the 
researchers or the patients. However, since this was a non-inferiority study and its results are 
objective, the lack of blinding is not likely to have significant effects on the outcome. 
Additionally, no placebo group was used for comparison. For this reason, the data from this 
study cannot conclude that the effects of PTX are inferior nor superior to those of prednisolone 
in the treatment of severe alcoholic hepatitis in adult patients. Furthermore, this study utilized a 
very small sample size, which makes skewed data more likely.4 
Based on its limitations and low quality of evidence, the results of this study4 were not 
significant. Therefore, solid conclusions cannot be drawn from the data provided. This study 
indicates the need for additional research to further evaluate the effectiveness of PTX as 
compared to prednisolone in the treatment of severe alcoholic hepatitis in adult patients. Perhaps 
future studies will include a larger sample size with blinding and a placebo group.  
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De et al  
This RCT9 also demonstrates several strengths and weaknesses. While it is a double-
blinded RCT, the sample size is very small making inaccurate data more likely. In addition, the 
researchers involved in this study bring up a valid point that no patients underwent liver biopsies 
to assess for histological improvement and TNF-a was not evaluated in patients taking PTX. 
This would be an important factor to measure in the PTX group, since this treatment is aimed at 
reducing its synthesis.  
Due to this study's limitations and low quality of evidence, the clinical decision to treat 
adult patients with severe alcoholic hepatitis with PTX rather than prednisolone should not be 
made without additional research. This area of medicine would benefit greatly from larger RCTs. 
Additionally, studies aimed at evaluating histological improvement and TNF-a factors could 
provide stronger evidence supporting the efficacy of prednisolone and PTX in the treatment of 
severe alcoholic hepatitis in adult patients.9 
CONCLUSION 
Alcoholic hepatitis is a chronic disease with significant mortality. Linked to excessive 
alcohol consumption, this debilitating disease has become a serious medical problem in the 
United States where the rates of chronic alcohol use remain high. Traditionally, this disease has 
been treated with a 28-day course of prednisolone. However, since the costs of prednisolone and 
PTX are comparable  and prednisolone has been linked to many serious adverse drug reactions, 
newer research is aimed at treating severe alcoholic hepatitis with PTX.  
The overall quality of evidence supporting the use of PTX rather than prednisolone in the 
treatment of severe alcoholic hepatitis in adult patients is low. However, there is indication that 
PTX may be a safer alternative to prednisolone in select patients. There is a lack of evidence and 
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good RCTs to support this theory, making it apparent that more research is needed to further 
evaluate the safety and efficacy of PTX and prednisolone in the treatment of severe alcoholic 
hepatitis in adult patients. Based on the results of this systematic review, further investigation 
with larger RCTs of longer duration is warranted to ensure patients are receiving the best 
treatment for alcoholic hepatitis with the least amount of risk.  
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Table I: Quality Assessment of Reviewed Articles 
Study Design 
Downgrade Criteria 
Upgrade 
Criteria 
Quality 
Limitations Indirectness Inconsistency Imprecision 
Publication 
bias 
Thursz et 
al8 
RCT Seriousa Not Serious Seriousb Not serious Not Likely None Low 
Park et al4 RCT Not 
Seriousc 
Not Serious Seriousb   Seriousd Not Likely None Low 
De et al9 RCT Not Serious 
 
Not Serious Seriousb Seriousd Not Likely None Low 
a The study stopped early for some patients due to lack of funding, resulting in the inability to evaluate for secondary endpoints 
b Results were inconsistent among all studies  
c  Lack of blinding; however, objective outcome measures were used  
d Small sample size  
